In 2021, a landmark trial published in the New England Journal of Medicine showed that semaglutide — the active ingredient in Ozempic — produced an average body weight reduction of 14.9% over 68 weeks in adults with obesity. That single data point rewired how medicine thinks about weight management. But semaglutide isn’t the only GLP-1 receptor agonist on the market, and as the class expands rapidly, the question men are increasingly asking isn’t just “does this work?” — it’s “which one is right for me, and how does it compare to the rest?”
Understanding the landscape of GLP-1 medications requires moving beyond brand recognition. Ozempic dominates the cultural conversation, but tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon) all occupy meaningful positions in clinical practice. Each has a distinct pharmacological profile, efficacy curve, and side effect burden — and the differences matter, especially for men who are serious about preserving muscle, improving metabolic markers, and optimizing their body composition rather than just watching the scale move.
How GLP-1 Medications Actually Work — And Why the Mechanism Matters
GLP-1, or glucagon-like peptide-1, is an incretin hormone naturally released by the gut in response to food. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety to the brain through the hypothalamus. GLP-1 receptor agonists mimic this hormone at the receptor level — but they do it with a much longer half-life than your body’s own GLP-1, which degrades in minutes. This sustained activation is what produces the clinically meaningful appetite suppression and glucose regulation that has made this drug class a breakthrough in metabolic medicine.
Semaglutide, the molecule behind Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management), is a second-generation GLP-1 agonist engineered with a fatty acid chain that binds to albumin in the blood. This modification extends its half-life to roughly seven days, which is why it’s dosed once weekly. Research published in the NEJM demonstrated that weekly subcutaneous semaglutide at 2.4 mg produced substantially greater weight loss than placebo in people without diabetes — an effect that went well beyond what had been achievable with older agents.
Liraglutide, the predecessor molecule (sold as Saxenda for weight loss), operates on the same receptor but has a shorter half-life requiring daily injections, and its peak efficacy for weight loss tops out at roughly 5–7% of body weight on average. It was meaningful progress when it launched, but the SCALE Obesity trial showed liraglutide at 3.0 mg produced an average loss of 8.4 kg versus 2.8 kg for placebo — respectable, but well below what semaglutide would later achieve. For men prioritizing convenience as part of long-term adherence, the once-weekly dosing advantage of semaglutide is not trivial.
Dulaglutide (Trulicity) is also once-weekly and approved primarily for type 2 diabetes, with cardiovascular outcome data supporting its use in that population. However, its weight loss effects are more modest than semaglutide at comparable dose escalations, and it hasn’t been approved as a standalone weight management agent in the way Wegovy has. Exenatide, the oldest agent in the class, is now largely a historical comparator — used by some practitioners but surpassed in nearly every metric by newer molecules.
Tirzepatide: The Dual-Agonist That Changed the Game
If semaglutide reset expectations for what pharmacological weight management could achieve, tirzepatide — the active ingredient in Mounjaro for diabetes and Zepbound for obesity — has reset them again. Tirzepatide is not a pure GLP-1 agonist. It is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist, meaning it activates two separate incretin pathways simultaneously. GIP receptors are expressed in fat tissue, and their co-activation appears to enhance the metabolic effects beyond what GLP-1 signaling alone can accomplish.
The SURMOUNT-1 trial, published in the NEJM in 2022, showed that tirzepatide at the highest dose (15 mg weekly) produced a mean weight reduction of 20.9% over 72 weeks. That’s not an incremental improvement over semaglutide — it’s a categorically different outcome for many patients, and it approaches the weight loss territory previously associated only with bariatric surgery. In head-to-head comparisons, tirzepatide has consistently outperformed semaglutide on both glycemic control and body weight reduction, though direct randomized trials comparing the two specifically for weight loss in non-diabetic populations are still maturing.
For men specifically, the body composition question is critical. Weight loss without attention to muscle preservation is a hollow victory — losing 20% of body weight that includes significant lean mass can impair strength, hormonal function, and long-term metabolic rate. Analysis from the SURMOUNT trials suggests that tirzepatide produces a greater proportion of fat mass loss relative to lean mass compared to lifestyle intervention alone, though muscle loss does occur and resistance training during treatment is strongly recommended for this reason. This holds true across all GLP-1 and dual-agonist therapies — the medication reduces appetite, but it doesn’t know the difference between fat and muscle unless you’re actively training and eating enough protein.
The practical implication is this: if you’re on any GLP-1 class medication and your protein intake drops below 1.6 grams per kilogram of body weight, and you’re not lifting, you are losing muscle. The drug doesn’t protect you from that. Resistance training and deliberate protein targeting — ideally 2.0–2.4 g/kg for men in a meaningful caloric deficit — are the non-negotiable complements to these therapies.
Side Effects, Tolerability, and What Men Often Don’t Ask About
The most common side effects across all GLP-1 medications are gastrointestinal: nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. These effects are dose-dependent and typically peak in the early weeks before subsiding as the body adapts. Semaglutide and tirzepatide share similar GI profiles, though some clinical data suggests tirzepatide may have slightly higher rates of nausea at initiation, which often resolves with slower titration schedules.
One underreported concern for men is the potential impact of aggressive caloric restriction — amplified by appetite suppression — on testosterone levels. Research has established that severe caloric deficits suppress luteinizing hormone pulsatility and can lower free testosterone, even in the short term. This doesn’t mean GLP-1 medications lower testosterone directly — the data on that is not definitive — but it does mean that men using these medications who are eating very little need to monitor their hormonal health and work with a physician who understands both metabolic and endocrine considerations. Adequate fat intake, caloric sufficiency above roughly 1,600–1,800 kcal for most men, and consistent training appear to mitigate this risk significantly.
There are also rare but serious concerns worth knowing: pancreatitis risk, though the absolute rate is low and causality debated in the literature; thyroid C-cell effects seen in rodent studies, which led to the black box warning on GLP-1 medications (clinical significance in humans at therapeutic doses remains unclear); and gallbladder disease, which appears elevated with rapid weight loss on these agents. None of these risks negate the substantial benefits for appropriate candidates, but they underscore why these are prescription medications requiring medical supervision rather than lifestyle supplements.
Oral semaglutide (Rybelsus) is worth a brief mention — it’s the first GLP-1 agonist formulated for daily oral administration, approved for type 2 diabetes. Bioavailability of the oral form is significantly lower than injectable semaglutide, and its weight loss data is more modest. It’s an option for men who have a strong aversion to injections, but for body composition goals, the injectable formulations currently have a clear efficacy advantage.
The Takeaway
The GLP-1 class has evolved rapidly from incremental diabetes drugs into a genuine paradigm shift in metabolic medicine. Within that class, the differences are real and clinically meaningful. Liraglutide delivers modest weight loss with a daily injection burden. Semaglutide delivers superior results with convenient weekly dosing and a robust cardiovascular outcomes dataset. Tirzepatide, with its dual GIP/GLP-1 mechanism, currently leads the class in weight loss efficacy and may offer additional metabolic advantages as its research base matures.
For men evaluating these options with their physician, the right choice depends on diabetes status, cardiovascular history, cost and insurance coverage, tolerance of side effects, and weight loss goals. But the medication is only half the equation. The men who get the best outcomes from any GLP-1 agent are the ones who use the appetite suppression as leverage — to eat more protein, train consistently, build better habits, and create a metabolic foundation that holds even if the medication is eventually discontinued. The drug buys you time and creates a caloric environment you couldn’t otherwise sustain. What you do with that environment determines whether the results last.